C S Chim
Overview
Explore the profile of C S Chim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
1462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lam K, Lam M, Chim C, Chan G, Li J
J Leukoc Biol
. 2020 Jun;
108(5):1565-1573.
PMID: 32480430
Extracellular vesicles (EVs) are nanosized particles that have emerged as mediators for intercellular communication in physiologic and pathologic conditions. EVs carry signaling information on their bilipid membrane as well as...
2.
Chim C, Kumar S, Orlowski R, Cook G, Richardson P, Gertz M, et al.
Leukemia
. 2019 Mar;
33(4):1058-1059.
PMID: 30842604
Following the publication of this article the authors noted that the MRD data under the Table 1 column "Remark" of Aspire should go to that of Pollux. The authors wish...
3.
Jurczyszyn A, Davila J, Kortum K, Jayabalan D, Vij R, Fiala M, et al.
Leuk Lymphoma
. 2018 Jul;
60(2):471-476.
PMID: 30033832
A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis...
4.
Chim C, Kumar S, Orlowski R, Cook G, Richardson P, Gertz M, et al.
Leukemia
. 2017 Dec;
32(2):252-262.
PMID: 29257139
Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to treat or which regimen to use at MM relapse/progression. Recent major randomized controlled trials...
5.
Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, et al.
Leukemia
. 2015 Dec;
30(5):1005-17.
PMID: 26710887
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level...
6.
Chim C, Wong K
Bone Marrow Transplant
. 2014 Aug;
49(12):1545-7.
PMID: 25133896
No abstract available.
7.
Hwang Y, Mohty M, Chim C
Hematology
. 2014 Jul;
20(2):61-71.
PMID: 24993587
Objectives: Myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a matched sibling donor (MSD) in first complete remission (CR1) is an effective consolidation for adult acute lymphoblastic leukemia (ALL), and...
8.
Ocio E, Richardson P, Rajkumar S, Palumbo A, Mateos M, Orlowski R, et al.
Leukemia
. 2013 Nov;
28(3):525-42.
PMID: 24253022
Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their combinations target specific aspects...
9.
Fernandez de Larrea C, Kyle R, Durie B, Ludwig H, Usmani S, Vesole D, et al.
Leukemia
. 2013 Jan;
27(4):780-91.
PMID: 23288300
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis...
10.